% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Brummer:278578,
      author       = {T. Brummer$^*$ and R. Zeiser$^*$},
      title        = {{T}he role of the {MDM}2/p53 axis in anti-tumor immune
                      responses},
      journal      = {Blood},
      volume       = {143},
      number       = {26},
      issn         = {0006-4971},
      address      = {Washington, DC},
      publisher    = {American Society of Hematology},
      reportid     = {DKFZ-2023-01659},
      pages        = {2701-2709},
      year         = {2024},
      note         = {2024 Jun 27;143(26):2701-2709},
      abstract     = {Mouse double minute 2 homolog (MDM2) is a negative
                      regulator of the tumor suppressor p53 and often highly
                      expressed in acute myeloid leukemia (AML) and different
                      solid tumors. Inactivating mutations in TP53, the gene
                      encoding for p53, confers an unfavorable prognosis in AML
                      and increases the risk for relapse after allogeneic
                      hematopoietic cell transplantation (allo-HCT). We review the
                      concept that manipulation of MDM2 and p53 could enhance
                      immunogenicity of AML and solid tumor cells. Additionally,
                      we discuss the mechanisms by which MDM2 and p53 regulate MHC
                      class I and II expression, transcription of dsRNA of
                      endogenous retroviruses, interferon responses, IL-15
                      production and TRAIL-receptor 1 and 2 expression on
                      malignant cells. The direct effects of MDM2-inhibition or
                      MDM2 deletion in effector T cells are discussed in the
                      context of cancer immunotherapy. The preclinical findings
                      are connected to clinical studies using MDM2-inhibition to
                      enhance anti-tumor immunity in patients. In aggregate, this
                      review summarizes current evidence supporting the use of
                      MDM2-inhibition to restore p53, as well as direct effects of
                      MDM2-inhibition on T cells as an emerging concept for
                      combined anti-tumor immunotherapy against hematological
                      malignancies and beyond.},
      subtyp        = {Review Article},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37467495},
      doi          = {10.1182/blood.2023020731},
      url          = {https://inrepo02.dkfz.de/record/278578},
}